CA2373239A1 - Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response - Google Patents
Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response Download PDFInfo
- Publication number
- CA2373239A1 CA2373239A1 CA002373239A CA2373239A CA2373239A1 CA 2373239 A1 CA2373239 A1 CA 2373239A1 CA 002373239 A CA002373239 A CA 002373239A CA 2373239 A CA2373239 A CA 2373239A CA 2373239 A1 CA2373239 A1 CA 2373239A1
- Authority
- CA
- Canada
- Prior art keywords
- sba
- agent according
- particles
- oil
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19923256.3 | 1999-05-20 | ||
DE19923256 | 1999-05-20 | ||
PCT/EP2000/004565 WO2000071154A2 (de) | 1999-05-20 | 2000-05-19 | Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2373239A1 true CA2373239A1 (en) | 2000-11-30 |
Family
ID=7908697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002373239A Abandoned CA2373239A1 (en) | 1999-05-20 | 2000-05-19 | Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1183045A2 (ja) |
JP (1) | JP2003500365A (ja) |
KR (1) | KR20020012221A (ja) |
AU (2) | AU5214200A (ja) |
BR (1) | BR0010823A (ja) |
CA (1) | CA2373239A1 (ja) |
DE (1) | DE10024788A1 (ja) |
MX (1) | MXPA01011660A (ja) |
TR (1) | TR200103333T2 (ja) |
WO (2) | WO2000071154A2 (ja) |
ZA (1) | ZA200109147B (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5214200A (en) * | 1999-05-20 | 2000-12-12 | Pharmasol Gmbh | Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
ES2425392T3 (es) | 2002-03-20 | 2013-10-15 | Mannkind Corporation | Cartucho para un aparato de inhalación |
JP2007509164A (ja) * | 2003-10-23 | 2007-04-12 | カイロン コーポレイション | 安定化組成物 |
FR2873386B1 (fr) | 2004-07-22 | 2011-01-14 | Agence Francaise De Securite Sanitaire Des Aliments Afssa | Composition vaccinale contre le rhodococcus equi |
ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
PL1791542T3 (pl) | 2004-08-23 | 2015-11-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
DK2570147T3 (da) | 2008-06-13 | 2018-01-29 | Mannkind Corp | Tørpulverinhalator og system til lægemiddelindgivelse |
KR101628410B1 (ko) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법 |
TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US8734845B2 (en) | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
MY180552A (en) | 2011-04-01 | 2020-12-02 | Mannkind Corp | Blister package for pharmaceutical cartridges |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
EP2844195B1 (en) | 2012-04-30 | 2019-03-20 | Össur HF | Prosthetic device, system and method for increasing vacuum attachment |
CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
EP3386540A1 (en) * | 2015-12-08 | 2018-10-17 | GlaxoSmithKline Biologicals S.A. | Novel adjuvant formulations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19745950A1 (de) * | 1997-10-17 | 1999-04-22 | Dds Drug Delivery Service Ges | Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation |
EP1100464A1 (en) * | 1998-07-31 | 2001-05-23 | Korea Institute Of Science And Technology | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier |
AU5214200A (en) * | 1999-05-20 | 2000-12-12 | Pharmasol Gmbh | Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response |
-
2000
- 2000-05-19 AU AU52142/00A patent/AU5214200A/en not_active Abandoned
- 2000-05-19 KR KR1020017014653A patent/KR20020012221A/ko not_active Application Discontinuation
- 2000-05-19 DE DE10024788A patent/DE10024788A1/de not_active Ceased
- 2000-05-19 CA CA002373239A patent/CA2373239A1/en not_active Abandoned
- 2000-05-19 JP JP2000619456A patent/JP2003500365A/ja not_active Withdrawn
- 2000-05-19 BR BR0010823-5A patent/BR0010823A/pt not_active IP Right Cessation
- 2000-05-19 MX MXPA01011660A patent/MXPA01011660A/es unknown
- 2000-05-19 WO PCT/EP2000/004565 patent/WO2000071154A2/de not_active Application Discontinuation
- 2000-05-19 EP EP00936761A patent/EP1183045A2/de not_active Withdrawn
- 2000-05-19 TR TR2001/03333T patent/TR200103333T2/xx unknown
- 2000-05-22 AU AU58091/00A patent/AU5809100A/en not_active Abandoned
- 2000-05-22 WO PCT/EP2000/004644 patent/WO2000071077A2/en not_active Application Discontinuation
-
2001
- 2001-11-06 ZA ZA200109147A patent/ZA200109147B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200109147B (en) | 2002-05-08 |
TR200103333T2 (tr) | 2002-04-22 |
BR0010823A (pt) | 2002-03-05 |
KR20020012221A (ko) | 2002-02-15 |
AU5809100A (en) | 2000-12-12 |
DE10024788A1 (de) | 2000-11-23 |
WO2000071154A2 (de) | 2000-11-30 |
AU5214200A (en) | 2000-12-12 |
MXPA01011660A (es) | 2004-04-05 |
WO2000071154A3 (de) | 2001-06-28 |
EP1183045A2 (de) | 2002-03-06 |
WO2000071077A2 (en) | 2000-11-30 |
JP2003500365A (ja) | 2003-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2373239A1 (en) | Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response | |
JP6625587B2 (ja) | Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 | |
Mohanan et al. | Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems | |
EP1574210B1 (en) | Microemulsions with adsorbed macromolecules | |
CN1980638B (zh) | 用糖脂稳定基于脂质的佐剂制剂的组合物和方法 | |
US8277823B2 (en) | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids | |
CN100384473C (zh) | 油佐剂疫苗 | |
US20200405846A1 (en) | Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration | |
Kallerup et al. | Influence of trehalose 6, 6′-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes | |
JP7409594B2 (ja) | 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 | |
CN103784953A (zh) | 作为疫苗佐剂的水包油型亚微乳及其制备方法 | |
CA2672338C (en) | Archaeal polar lipid aggregates for administration to animals | |
Perrie et al. | Recent developments in particulate-based vaccines | |
CN104043119A (zh) | 一种新型疫苗佐剂及其制备方法 | |
Myschik et al. | Immunostimulatory lipid implants containing Quil-A and DC-cholesterol | |
AU744308B2 (en) | Antigen vectors in the form of multilamellar vesicles | |
US20100209452A1 (en) | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof | |
Ariaee et al. | Mucosal adjuvant potential of Quillaja saponins and cross-linked dextran microspheres, co-administered with liposomes encapsulated with tetanus toxoid | |
JP2019202957A (ja) | 免疫組成物 | |
CN111166890A (zh) | 一种缓释疫苗载体及其制备方法 | |
WO2011138050A1 (en) | Method for vaccination | |
US20220000779A1 (en) | Immunogenic compositions | |
Turánek et al. | Functionalised nanoliposomes for construction of recombinant vaccines: lyme disease as an example | |
Wilkhu et al. | Developing Bilayer-Based Delivery Systems for Oral Delivery of Subunit Vaccines | |
Christensen et al. | Liposomes in adjuvant systems for parenteral delivery of vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20060519 |